Bag S, et al. – The objective here was to determine the proteomic signatures from biopsies that could be used as precancer diagnostic marker for patients suffering from oral submucous fibrosis (OSF). The findings identified and validated α–enolase as a novel biomarker for the initial diagnosis of malignant potentiality of OSF. The α–enolase could assist in early therapeutic intervention of OSF patients, which would cause a reduction of patient’s pain, therapeutic cost and enhancement of patient’s quality of life.